Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it is collaborating with Cancer Research UK to validate a microRNA as a biomarker for the prediction of progression-free survival in patients with metastatic colorectal cancer who have received anti-EGFR therapy.

According to the company, recent data from researchers at the French Institute of Health and Medical Research show that expression of the miRNA, called miR-31-3p, in primary tumor samples is associated with anti-EGFR response in KRAS wild-type patients with the disease who have been treated with EGFR inhibitors.

In collaboration with researchers from Cancer Research UK, who have investigated the use of anti-EGFR antibodies in KRAS wild-type patients with colorectal cancer, IntegraGen will further investigate the expression of miR-31-3p in both primary and metastatic tumors to determine its ability to predict patient outcomes.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.